T
Thomas Wiegel
Researcher at University of Ulm
Publications - 44
Citations - 2227
Thomas Wiegel is an academic researcher from University of Ulm. The author has contributed to research in topics: Prostatectomy & Prostate cancer. The author has an hindex of 15, co-authored 44 publications receiving 1899 citations.
Papers
More filters
Journal ArticleDOI
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp,Roger Stupp,Monika E. Hegi,Thierry Gorlia,Sara Erridge,James Perry,Yong-Kil Hong,Kenneth Aldape,Benoit Lhermitte,Torsten Pietsch,Danica Grujicic,Joachim P. Steinbach,Wolfgang Wick,Rafal Tarnawski,Do-Hyun Nam,Peter Hau,Astrid Weyerbrock,Martin J B Taphoorn,Chiung-Chyi Shen,Nalini Rao,László Thurzó,Ulrich Herrlinger,Tejpal Gupta,Rolf-Dieter Kortmann,Krystyna Adamska,Catherine McBain,Alba A. Brandes,Joerg C. Tonn,Oliver Schnell,Thomas Wiegel,Chae-Yong Kim,Louis B. Nabors,David A. Reardon,Martin J. van den Bent,Christine Hicking,Andriy Markivskyy,Martin Picard,Michael Weller +37 more
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI
Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
Ludwig Rinnab,Felix M. Mottaghy,N. M. Blumstein,Sven N. Reske,Richard E. Hautmann,Kathrin Hohl,Peter Möller,Thomas Wiegel,Rainer Kuefer,Juergen E. Gschwend +9 more
TL;DR: To evaluate [11C]‐choline positron‐emission tomography (PET/computed tomography) for detecting clinical recurrence after primary treatment for prostate cancer.
Journal ArticleDOI
Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Thomas Wiegel,Gunnar Lohm,D. Bottke,S. Höcht,Kurt Miller,Alessandra Siegmann,Martin Schostak,Konrad Neumann,Wolfgang Hinkelbein +8 more
TL;DR: It is suggested that achieving an undetectable PSA after RT is an important prognosticator for a high chance of cure and patients with a low PSA pre-SRT, positive surgical margins, and low tumor stage at the time of RP are best candidates for SRT.
Journal ArticleDOI
EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease - Guía de la EAU sobre el cáncer de próstata. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado
Axel Heidenreich,Joaquim Bellmunt,M. Bolla,Steven Joniau,Malcolm David Mason,Vsevolod Matveev,N. Mottet,Hans Schmid,T.H. Van Der Kwast,Thomas Wiegel,F. Zattoni +10 more
TL;DR: Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa, and active surveillance represents a viable option in men with low-risk PCa and a long life expectancy.